Antibody Drug Conjugates or ADCs are a new class of highly potent biopharmaceutical drugs designed as a Targeted therapy for the treatment of people with cancer. ADCs are complex molecules composed of an antibody (a whole mAb or an antibody fragment such as a single-chain variable fragment [scFv]) linked, via a stable, chemical, linker with labile bonds, to a biological active cytotoxic (anticancer) payload or drug. Antibody Drug Conjugates are examples of bioconjugates and immunoconjugates.
By combining the unique targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs, antibody-drug conjugates allow sensitive discrimination between healthy and diseased tissue. This means that, in contrast to traditional chemotherapeutic agents, antibody-drug conjugates target and attack the cancer cell so that healthy cells are less severely affected.
How do ADCs work?
In developing antibody-drug conjugates, an anticancer drug (e.g. a cell toxin or cytotoxin) is coupled to an antibody that specifically targets a certain tumor marker (e.g. a protein that, ideally, is only to be found in or on tumor cells). Antibodies track these proteins down in the body and attach themselves to the surface of cancer cells. The biochemical reaction between the antibody and the target protein (antigen) triggers a signal in the tumor cell, which then absorbs or internalizes the antibody together with the cytotoxin. After the ADC is internalized, the cytotoxic drug is released and kills the cancer. Due to this targeting, ideally the drug has lower side effects and gives a wider therapeutic window than other chemotherapeutic agents. These advantages have led to ADC technologies being featured in many publications, notably the New York Times, as well as numerous scientific journals.
To date, only three ADCs have received market approval. However, after a request from the U.S. Food and Drug Administration (FDA), Pfizer/Wyeth, the developer and marketer of the first ADC to receive marketing approval in 2001 for the treatment of patients with acute myelogenous leukemia (Gemtuzumab ozogamicin, trade name: Mylotarg), withdrew the drug from the market in June 2010. As a result, only two ADC are marketed (2013), including Brentuximab vedotin (trade name: Adcetris, marketed by Seattle Genetics and Millennium/Takeda) and Trastuzumab emtansine (trade name: Kadcyla, marketed by Genentech and Roche).
Brentuximab vedotin was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on August 19, 2011 for relapsed HL and relapsed sALCL and conditional Marketing authorization from the European Medicines Agency in October 2012 for relapsed or refractory HL and relapsed or refractory sALCL. Trastuzumab emtansine (ado-trastuzumab emtansine or T-DM1) was approved in February 2013 for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with trastuzumab (Herceptin®, Genentech and Roche) and a taxane chemotherapy.
A stable link between the antibody and cytotoxic (anti-cancer) agent is a crucial aspect of an ADC. Linkers are based on chemical motifs including disulfides, hydrazones or peptides (cleavable), or thioethers (noncleavable) and control the distribution and delivery of the cytotoxic agent to the target cell. Cleavable and noncleavable types of linkers have been proven to be safe in preclinical and clinical trials. Brentuximab vedotin includes an enzyme-sensitive cleavable linker that delivers the potent and highly toxic antimicrotubule agent Monomethyl auristatin E or MMAE, a synthetic antineoplastic agent, to human specific CD30-positive malignant cells. Because of its high toxicity MMAE, which inhibits cell division by blocking the polymerization of tubulin, cannot be used as a single-agent chemotherapeutic drug. However, the combination of MMAE linked to an anti-CD30 monoclonal antibody (cAC10, a cell membrane protein of the tumor necrosis factor or TNF receptor) proved to be stable in extracellular fluid, cleavable by cathepsin and safe for therapy. Trastuzumab emtansine, the other approved ADC, is a combination of the microtubule-formation inhibitor mertansine (DM-1), a derivative of the Maytansine, and antibody trastuzumab (Herceptin®/ Genentech/Roche) attached by a stable, non-cleavable linker.
The availability of better and more stable linkers has changed the function of the chemical bond. The type of linker, cleavable or noncleavable, lends specific properties to the cytotoxic (anti-cancer) drug. For example, a non-cleavable linker keeps the drug within the cell. As a result, the entire antibody, linker and cytotoxic (anti-cancer) agent enter the targeted cancer cell where the antibody is degraded to the level of an amino acid. The resulting complex – amino acid, linker and cytotoxic agent – now becomes the active drug. In contrast, cleavable linkers are catalyzed by enzymes in the cancer cell where it releases the cytotoxic agent. The difference is that the cytotoxic payload delivered via a cleavable linker can escape from the targeted cell and, in a process called “bystander killing,” attack neighboring cancer cells.
Another type of cleavable linker, currently in development, adds an extra molecule between the cytotoxic drug and the cleavage site. This linker technology allows researchers to create ADCs with more flexibility without worrying about changing cleavage kinetics. Researchers are also developing a new method of peptide cleavage based on Edman degradation, a method of sequencing amino acids in a peptide. Future direction in the development of ADCs also include the development of site-specific conjugation (TDCs)  to further improve stability and therapeutic index and α emitting immunoconjugates  and antibody-conjugated nanoparticles.
Other disease areas
The majority of the ADCs currently under development or in clinical trials are for oncological and hematological indications. This is primarily driven by the availability of monoclonal antibodies targeting various types of cancer. However, some drug developers are also looking to expanding the application of ADCs beyond oncology and hematology to other important disease areas. At this time, these ADCs are only in initial drug discovery or preclinical stage of development.
- Antibody-Drug Conjugates: Guided Missiles Deployed Against Cancerous Cells 
- What are ADCs? "ADC Review / Journal of Antibody-drug Conjugates", - June 1, 2013 
- The Next Advancements in Cancer Drug Development: Antibody-Drug Conjugates - Onco'Zine - The International Cancer Network, June 14, 2012 
- Antibody Drug Conjugates: A Marriage of Biologics and Small Molecules - Pharmaceutical Technology. Pharmtech.findpharma.com. Retrieved on 2010-11-20.
- Ducry, Laurent; Stump, Bernhard (2010). "Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies". Bioconjugate Chemistry 21 (1): 5–13. doi:10.1021/bc9002019. PMID 19769391.
- Kovtun, Y. V.; Audette, CA; Ye, Y; Xie, H; Ruberti, MF; Phinney, SJ; Leece, BA; Chittenden, T et al. (2006). "Antibody-Drug Conjugates Designed to Eradicate Tumors with Homogeneous and Heterogeneous Expression of the Target Antigen". Cancer Research 66 (6): 3214–21. doi:10.1158/0008-5472.CAN-05-3973. PMID 16540673.
- Kovtun, YV; Goldmacher, VS (2007). "Cell killing by antibody-drug conjugates". Cancer letters 255 (2): 232–40. doi:10.1016/j.canlet.2007.04.010. PMID 17553616.
- Antibody-Drug Conjugates Stage a Comeback
- DiJoseph JF, Armellino DC, Boghaert ER, Khandke K, Dougher MM, Sridharan L, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004 Mar 1;103(5):1807-14. Epub 2003 Nov 13. 
- Mullard A. Maturing antibody–drug conjugate pipeline hits 30. Nature Reviews Drug Discovery 12, 329–332 (May 2013) doi:10.1038/nrd4009 
- Chari, Ravi V. J.; Martell, Bridget A.; Gross, Jonathan L.; Cook, Sherrilyn B.; Shah, Sudhir A.; Blättler, Walter A.; McKenzie, Sara J.; Goldmacher, Victor S. (1992). "Immunoconjugates containing novel maytansinoids: promising anticancer drugs". Cancer Research 52 (1): 127–31. PMID 1727373.
- , Pollack A. May 31, 2012. In print on June 1, 2012, on page B1 of the New York edition with the headline: A One-Two Punch.
- , Published June 3, 2012
- Mylotarg (gemtuzumab ozogamicin): Market Withdrawal, US FDA
- FDA Approves Genentech's Kadcyla (Ado-Trastuzumab Emtansine), the First Antibody-Drug Conjugate for Treating Her2-Positive Metastatic Breast Cancer 
- Safety Assessment of Antibody Drug Conjugates
- Ado-trastuzumab emtansine (U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute) 
- Kovtun YV, Goldmacher VS. Cell killing by antibody-drug conjugates. Cancer Lett. 2007 Oct 8;255(2):232-40. Epub 2007 Jun 5.
- Bąchor R, Kluczyk A, Stefanowicz P, Szewczuk Z. New method of peptide cleavage based on Edman degradation. Mol Divers. 2013 May 21. (Epub ahead of print)
- Axup JY, Bajjuri KM, Ritland M, Hutchins BM, Kim CH, Kazane SA, Halder R, et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16101-6. doi: 10.1073/pnas.1211023109. Epub 2012 Sep 17. 
- Wulbrand C, Seidl C, Gaertner FC, Bruchertseifer F, Morgenstern A, Essler M, Senekowitsch-Schmidtke R. Alpha-Particle Emitting (213)Bi-Anti-EGFR Immunoconjugates Eradicate Tumor Cells Independent of Oxygenation. PLoS One. 2013 May 28;8(5):e64730. doi: 10.1371/journal.pone.0064730. Print 2013 
- Cardoso MM, Peça IN, Roque AC. Antibody-conjugated nanoparticles for therapeutic applications. Curr Med Chem. 2012;19(19):3103-27. 
- Flygare JA, Pillow TH, Aristoff P. Antibody-drug conjugates for the treatment of cancer.Chem Biol Drug Des. 2013 Jan;81(1):113-21. doi: 10.1111/cbdd.12085.
- Ambrx Collaborates with Merck to Design and Develop Biologic Drug Conjugates